Trial Profile
A phase II trial of copper gluconate/disulfiram (CX-02) in patients with metastatic prostrate cancer
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 11 Apr 2017
Price :
$35
*
At a glance
- Drugs Copper-gluconate/disulfiram (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 11 Apr 2017 New trial record
- 04 Apr 2017 This trial is expected to begin in the second half of 2017, according to a Cantex Pharmaceuticals media release.